Physician profile
Vicky Brooks
NPI 1336447838
$2,643.34
in general payments reported to CMS, 2019-2025
21 companies · $579 in 2025
The $579 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $265 · 2022: $543 · 2023: $500 · 2024: $756 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,835.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $410.89 | 2022-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $390.63 | 2021-2025 | |
| Pfizer INC. | $306.48 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $273.20 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $195.94 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $182.97 | 2023-2025 | Rybelsus, Ozempic |
| Cvrx, INC. | $144.74 | 2023 | Barostim Neo System |
| Janssen Biotech, INC. | $120.28 | 2022 | |
| Angiodynamics, INC. | $108.70 | 2021 | |
| Lilly USA, LLC | $101.85 | 2022-2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $72.09 | 2022 | |
| Sumitomo Pharma America, INC. | $61.16 | 2023-2024 | Gemtesa |
| Exact Sciences Corporation | $56.25 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $49.33 | 2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $44.66 | 2022-2025 | Capvaxive, Gardasil 9 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $35.03 | 2022 | |
| Ibsa Pharma INC. | $22.18 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.24 | 2022 | |
| Currax Pharmaceuticals LLC | $16.19 | 2024 | Contrave |
| Nestle Healthcare Nutrition INC. | $15.62 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicky Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.